WallStSmart

Crowdstrike Holdings Inc (CRWD)vsCommScope Holding Company, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Crowdstrike Holdings Inc generates 139% more annual revenue ($4.81B vs $2.02B). VISN leads profitability with a 347.7% profit margin vs -3.4%. VISN appears more attractively valued with a PEG of 2.94. VISN earns a higher WallStSmart Score of 74/100 (B).

CRWD

Hold

40

out of 100

Grade: D

Growth: 9.3Profit: 2.5Value: 3.0Quality: 6.0
Piotroski: 2/9Altman Z: 1.00

VISN

Strong Buy

74

out of 100

Grade: B

Growth: 6.7Profit: 6.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: 0.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CRWDSignificantly Overvalued (-79.7%)

Margin of Safety

-79.7%

Fair Value

$373.43

Current Price

$671.02

$297.59 premium

UndervaluedFair: $373.43Overvalued

Intrinsic value data unavailable for VISN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRWD4 strengths · Avg: 9.0/10
EPS GrowthGrowth
533.0%10/10

Earnings expanding 533.0% YoY

Market CapQuality
$195.73B9/10

Large-cap with strong market position

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
23.3%8/10

Revenue surging 23.3% year-over-year

VISN6 strengths · Avg: 9.3/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Profit MarginProfitability
347.7%10/10

Keeps 348 of every $100 in revenue as profit

EPS GrowthGrowth
704.0%10/10

Earnings expanding 704.0% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

P/E RatioValuation
17.3x8/10

Attractively priced relative to earnings

Revenue GrowthGrowth
21.6%8/10

Revenue surging 21.6% year-over-year

Areas to Watch

CRWD4 concerns · Avg: 2.5/10
Operating MarginProfitability
1.0%3/10

Operating margin of 1.0%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
6.452/10

Expensive relative to growth rate

Price/BookValuation
38.4x2/10

Trading at 38.4x book value

VISN3 concerns · Avg: 2.0/10
PEG RatioValuation
2.942/10

Expensive relative to growth rate

Free Cash FlowQuality
$-228.80M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CRWD

The strongest argument for CRWD centers on EPS Growth, Market Cap, Debt/Equity. Revenue growth of 23.3% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Price/Book, Profit Margin, EPS Growth. Profitability is solid with margins at 347.7% and operating margin at 7.1%. Revenue growth of 21.6% demonstrates continued momentum.

Bear Case : CRWD

The primary concerns for CRWD are Operating Margin, Piotroski F-Score, PEG Ratio.

Bear Case : VISN

The primary concerns for VISN are PEG Ratio, Free Cash Flow, Altman Z-Score.

Key Dynamics to Monitor

VISN carries more volatility with a beta of 1.93 — expect wider price swings.

CRWD is growing revenue faster at 23.3% — sustainability is the question.

CRWD generates stronger free cash flow (493M), providing more financial flexibility.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VISN scores higher overall (74/100 vs 40/100), backed by strong 347.7% margins and 21.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Crowdstrike Holdings Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

CrowdStrike Holdings, Inc. provides cloud solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. The company is headquartered in Sunnyvale, California.

Visit Website →

CommScope Holding Company, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?